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Abstract
Fibroblast growth factors (FGFs) play key roles in the pathogenesis
of different human diseases, but the cross-talk between FGFs and
other cytokines remains largely unexplored. We identified an unex-
pected antagonistic effect of FGFs on the interferon (IFN) signaling
pathway. Genetic or pharmacological inhibition of FGF receptor
signaling in keratinocytes promoted the expression of interferon-
stimulated genes (ISG) and proteins in vitro and in vivo. Conversely,
FGF7 or FGF10 treatment of keratinocytes suppressed ISG expres-
sion under homeostatic conditions and in response to IFN or poly(I:C)
treatment. FGF-mediated ISG suppression was independent of IFN
receptors, occurred at the transcriptional level, and required FGF
receptor kinase and proteasomal activity. It is not restricted to
keratinocytes and functionally relevant, since FGFs promoted the
replication of herpes simplex virus I (HSV-1), lymphocytic chorio-
meningitis virus, and Zika virus. Most importantly, inhibition of
FGFR signaling blocked HSV-1 replication in cultured human kera-
tinocytes and in mice. These results suggest the use of FGFR kinase
inhibitors for the treatment of viral infections.
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Introduction
Fibroblast growth factors (FGFs), which comprise a family of 22
proteins, are master regulators of development and tissue repair,
and abnormalities in FGF signaling are involved in the pathogenesis
of major human diseases, including developmental and inflamma-
tory diseases and cancer (Beenken & Mohammadi, 2009; Ornitz &
Itoh, 2015). Most FGFs signal through one or more of four receptor
tyrosine kinases, designated FGF receptor (FGFR)1 to FGFR4. Addi-
tional complexity is achieved by alternative splicing, resulting in the
production of FGFR splice variants with different ligand binding
specificities (Ornitz & Itoh, 2015). Expression of most FGFs is low
under homeostatic conditions, but induced upon injury to various
tissues and organs, which is essential for efficient tissue repair and
regeneration (Maddaluno et al, 2017). Therefore, recombinant FGFs
are clinically used for the promotion of tissue repair, such as cuta-
neous wound healing, and for the protection of tissues from dif-
ferent types of damage (Nunes et al, 2016; Zhang & Li, 2016). On
the other hand, enhanced expression of FGFs or FGFRs and/or
abnormal FGFR signaling is frequently observed in cancer, and
FGFR inhibitors are therefore in clinical trials for the treatment of
various malignancies (Tanner & Grose, 2016). Given these impor-
tant activities of FGFs, it is paramount to identify the mechanisms
of action of FGFs, the responsible target genes, and the cross-talk
between FGFs and other growth factors and cytokines.
To study FGF function in the skin, we previously generated mice
lacking FGFR1, FGFR2, or both receptors in keratinocytes of the
epidermis and hair follicles. These mice develop a progressive
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inflammatory skin disease with features resembling atopic dermati-
tis in humans, which results at least in part from a defect in the
epidermal barrier (Yang et al, 2010). However, the epidermal and
immune phenotype only develops around 3 weeks after birth, and
therefore, young mice are ideally suited for the identification of
direct targets of FGF signaling in the epidermis.
Here, we show that expression of various ISGs is suppressed by
FGFs in keratinocytes and correlates with enhanced replication of
different types of viruses. These results identify FGF receptor inhibi-
tors as promising compounds for antiviral therapies.
Results
Inhibition of FGFR signaling promotes expression of
IFN-stimulated genes in keratinocytes
To identify FGF targets in the epidermis, we performed microarray
analysis of epidermal RNA from mice lacking FGFR1 and FGFR2 in
keratinocytes (K5-R1/R2 mice) and control mice without Cre recom-
binase (Yang et al, 2010) at postnatal day 18 (P18) and thus prior to
the development of skin inflammation and epidermal thickening.
Functional enrichment analysis of the differentially regulated genes
(log2(f.c.) > 1.5, P < 0.05) identified enriched ontologies and path-
ways that reflect the epidermal abnormalities of K5-R1/R2 mice and
the loss of hair follicles and associated melanocytes (Table 1A and
B). Remarkably, the top hits are genes characteristic for the “Type I
Interferon Response” (Table 1A and B, and Dataset EV1), and at
least 15% (11/63) of the genes that were upregulated in K5-R1/R2
epidermis compared with controls (log2(f.c.) > 1.5, P < 0.05), in
particular the majority of the most strongly regulated genes, are
classical IFN-stimulated genes (ISGs) (Table 1C). Upregulation of
ISGs was confirmed by qRT–PCR analysis of epidermal RNA from
adult mice for some of the genes identified in the microarray and for
additional ISGs, including IFN response factor 7 (Irf7), radical
S-adenosyl methionine domain containing 2 (Rsad2), 20-50-oligoade-
nylate synthetase-like 2 (Oasl2), IFN-induced protein with tetratri-
copeptide repeat 1 (Ifit1), signal transducer and activator of
transcription 1 (Stat1), and Stat2 (Fig 1A). Upregulation of some
ISGs was already significant at day 5 after birth (P5) and very robust
at P9 (Fig 1B) and thus prior to the development of the barrier
defect and associated cutaneous abnormalities and concomitant
with the complete deletion of the Fgfr1 and Fgfr2 genes (Yang et al,
2010; Sulcova et al, 2015).
Elevated expression of IRF7 in the epidermis of adult K5-R1/R2
mice was confirmed by strong immunostaining in the nuclei of basal
and suprabasal keratinocytes of the mutant mice (Fig 1C, red dots
indicated by arrows). The nuclear localization of IRF7, which
together with IRF3 and NF-jB controls the expression of interferons
type I (IFN-a and IFN-b) and type III (IFN-k), hints at enhanced
production of IFNs in the epidermis of FGFR1/R2-deficient mice.
Indeed, Ifnb and Ifnl3 expression was significantly increased in
freshly isolated, non-cultured keratinocytes from the epidermis of
K5-R1/R2 mice, concomitantly with all tested ISGs. This was already
seen at P7 and thus preceding the increase in immune cells (Fig 1D).
Upregulation of ISG expression is a cell-autonomous effect, since
it was also observed in cultured primary keratinocytes from neonate
K5-R1/R2 mice (Fig 1E). However, it was less pronounced
compared with non-cultured, freshly isolated keratinocytes (P7),
suggesting that IFNs produced by immune cells in vivo potentiate
this effect. An effect of Cre recombinase on ISG expression was
excluded, since the expression levels of these genes were similar in
primary keratinocytes isolated from the epidermis of wild-type and
K5-Cre mice (Fig 1F). Upregulation of ISG expression in the absence
of FGFR1 and FGFR2 was confirmed at the protein level for IRF1,
IRF7, and IRF9 by Western blot analysis of total and in particular of
nuclear lysates of spontaneously immortalized keratinocytes from
K5-R1/R2 mice (Fig 1G).
The important role of FGFR signaling in the suppression of ISG
expression was confirmed when human immortalized keratinocytes
(HaCaT cells) were treated for 48 h with the FGFR kinase inhibitor
BGJ398 (Guagnano et al, 2011) in the presence of serum, which
contains low levels of FGFs. FGFR inhibition promoted expression of
ISGs, including RSAD2 and interferon-stimulated gene 15 (ISG15)
(Fig 1H).
FGFs suppress ISG expression in keratinocytes and intestinal
epithelial cells
To further determine whether FGF signaling directly regulates ISG
expression, we treated primary murine keratinocytes with FGF7, a
major ligand of the FGFR2 splice variant expressed on keratinocytes
(FGFR2b) (Ornitz & Itoh, 2015). Like many other cell types (Gough
et al, 2012), mouse keratinocytes show a tonic expression of various
ISGs. Treatment of these cells with FGF7 for only 3–6 h suppressed
the tonic expression of all ISGs that we tested (Fig 2A). This was
verified with HaCaT keratinocytes at the RNA level for ISGs, which
were also regulated in mouse keratinocytes and which have a human
orthologue with similar function (Fig 1 and Table 1C) and also for
additional ISGs that we tested with the human cells. In HaCaT cells,
FGF7 suppressed, for example, the expression of IRF7, RSAD2, and
IRF1 (Figs 2B and EV1A) and of suppressor of cytokine signaling 1
and 3 (SOCS1 and SOCS3) (Fig EV1A), which are ISG products and
involved in negative regulation of IFN signaling (Blumer et al, 2017;
Michalska et al, 2018). FGF10, which also activates FGFR2b and in
addition FGFR1b (Ornitz & Itoh, 2015), had a similar effect (Figs 2B
and EV1A). The effect of FGF7 was verified at the protein level for
IRF1 and IRF9 (Fig 2C, see also Fig 3C). By contrast, IRF3 expression
was not suppressed by FGF7 at the RNA or protein level (Figs EV1A
and 2C). The efficiency of FGF7 and FGF10 treatment in these experi-
ments was validated by analysis of the expression of dual-specific
phosphatase 6 (DUSP6), a classical FGF target gene that is strongly
upregulated in response to FGFs (Li et al, 2007; Fig EV1A).
The suppressive effect of FGF7 on ISG expression and the concomi-
tant increase in DUSP6 expression was also observed with the Caco-2
colon cancer cell line, which is responsive to FGF7 (Visco et al, 2009).
While IRF7 expression was not regulated by FGF7 in these cells, there
was a significant FGF7-induced reduction of the mRNA levels of IFIT1,
ISG15, and also of the pattern recognition receptor RIG-I [retinoic acid
inducible gene I (encoded by the DDX58 gene)], which upon ligand
binding promotes IFN expression (Bruns & Horvath, 2014; Fig EV1B).
RSAD2 mRNAwas not detectable in these cells.
The effect of FGF7 on ISG expression was dependent on the
FGFR kinase activity, since it was largely inhibited in primary
mouse keratinocytes or human HaCaT keratinocytes upon treatment
with the FGFR kinase inhibitors AZD4547 (Gavine et al, 2012) or
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BGJ398 (Guagnano et al, 2011; Fig EV2A and B). Blockade of the
major FGFR signaling pathways, the phosphatidylinositide 3-kinase
(PI3K)/AKT and MEK1/2-ERK1/2 pathways, mildly, but non-signifi-
cantly, reduced the effect of FGF7 on the expression of some ISGs in
HaCaT keratinocytes, while other ISGs were not affected
(Fig EV2C). Importantly, however, combined treatment with MEK1/
2 and PI3K inhibitors partially or completely blocked the effect of
FGF7 (Fig EV2C). By contrast, we did not observe an effect of phos-
pholipase Cc inhibition (Fig EV2D). Verification of the activity of
the inhibitors is shown in Appendix Fig S1.
In contrast to ISGs, IFN expression is hardly detectable in kera-
tinocytes under normal culture conditions, and therefore, it is unli-
kely that a further reduction in IFN protein levels contributes to
the effect of FGF7. Furthermore, expression of SOCS1 and SOCS3,
which inhibit IFN signaling by competing with STATs for receptor
binding and by suppression of JAK activity (Ivashkiv & Donlin,
2014), was even down-regulated by FGF7 or FGF10 (Fig EV1A).
Rather, the rapid suppression of the expression level of several
ISGs suggests that FGF7 regulates ISGs independent of IFN recep-
tors. To test this possibility, we treated primary keratinocytes from
mice lacking the IFN-a and IFN-b receptor (IFNAR) or double
knockout mice deficient in IFNAR and the IFN-k receptor (IFNLR)
with FGF7. As expected, expression levels of ISGs were signifi-
cantly lower in knockout compared to wild-type cells (Fig 2D), but
still detectable (Cp values around 27.5 in the cells from double
knockout mice). Nevertheless, the FGF7-induced suppression of
ISG expression was still observed in the absence of these receptors
(Fig 2E). These findings strongly suggest that FGF7 signaling
Table 1. Type I interferon signaling is the top regulated pathway in the epidermis of K5-R1/R2 mice.
(A) Gene Ontology (GO) Biological Process 2017b
Index Name P-value Adj P-value
1 Negative regulation of single stranded viral RNA replication via double-stranded DNA intermediate (GO:0045869) 0.000008 0.001836
2 Negative regulation of viral genome replication (GO:0045071) 0.000006 0.001836
3 Negative regulation by host of viral genome replication (GO:0044828) 0.000015 0.002497
4 Melanin biosynthetic process from tyrosine (GO:0006583) 0.000000 0.000315
5 Skin epidermis development (GO:0098773) 0.000171 0.006386
6 Defense response to fungus (GO:0050832) 0.000379 0.006386
7 Antifungal innate immune response (GO:0061760) 0.000379 0.006386
8 Defense response to fungus, incompatible interaction (GO:0009817) 0.000379 0.006386
9 Neutrophil-mediated killing of fungus (GO:0070947) 0.000379 0.006386
10 Negative regulation of single stranded viral RNA replication via double-stranded DNA intermediate (GO:0045869) 0.000008 0.001836
(B) Reactome 2016
Index Name P-value Adj P-value
1 Interferon alpha/beta signaling_Homo sapiens_R-HSA-909733 0.000017 0.001495
2 Interferon Signaling_Homo sapiens_R-HSA-913531 0.000870 0.039131
3 Glutathione conjugation_Homo sapiens_R-HSA-156590 0.003484 0.104528
4 Antiviral mechanism by IFN-stimulated genes_Homo sapiens_R-HSA-1169410 0.011532 0.207580
5 ISG15 antiviral mechanism-Homo sapiens_R-HSA-1169408 0.011532 0.207580
(C) ISGs that are upregulated (log2(f.c.) > 1.5, P < 0.05) in the epidermis of K5-R1/R2 mice at P18 (microarray data)
Gene
Symbol Description Gene ID Affy Probe ID Log2(f.c.) P-value
Rtp4 Receptor transporter protein 4 67775 1418580_at 2.841 0.003
Rsad2 Radical S-adenosyl methionine domain containing 2 58185 1421009_at 2.824 0.007
Il1f8 Interleukin 1 family, member 8 69677 1425715_at 2.652 0.014
Ifit1 Interferon-induced protein with tetratricopeptide repeats 1 15957 1450783_at 2.649 0.014
Rsad2 Radical S-adenosyl methionine domain containing 2 58185 1436058_at 2.589 0.021
Ifi27l2a Interferon, alpha-inducible protein 27 like 2A 76933 1426278_at 2.506 0.021
Ifi44 Interferon-induced protein 44 99899 1423555_a_at 2.493 0.004
Isg15 ISG15 ubiquitin-like modifier 100038882 1431591_s_at 2.027 0.009
Rsad2 Radical S-adenosyl methionine domain containing 2 58185 1421008_at 1.931 0.009
Oas1d 20-50-oligoadenylate synthetase 1D 100535 1416847_s_at 1.879 0.039
Defb3 Defensin beta 3 27358 1421806_at 1.56 0.044
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directly affects the transcription of ISGs. Consistent with this
assumption, FGF7 suppressed the basal expression level of a luci-
ferase reporter gene driven by five interferon-stimulated response
elements (ISRE) in HaCaT cells (Fig 2F). Since the effect of FGF7
is rapid, it may be the consequence of FGF7-mediated degradation
of a protein required for efficient ISG transcription. Indeed, the
effect of FGF7 was abolished in the presence of the proteasome
inhibitors MG132, epoxomicin, or bortezomib (Fig 2G and H, and
Appendix Fig S2A). The activity of the proteasome inhibitors was
verified by Western blot analysis of the nuclear factor erythroid 2-
related factor 2 (NRF2) transcription factor, which is rapidly
degraded by the proteasome under normal conditions (Villeneuve
et al, 2010; Appendix Fig S2B).
FGF7 suppresses IFN-induced ISG expression
We next tested whether FGF7 also suppresses the response of kerati-
nocytes to exogenous IFNs. Indeed, the IFN-a-induced upregulation
of ISG expression in HaCaT cells was at least in part suppressed by
FGF7 (Fig 3A). FGF7 exerted this effect in a dose-dependent manner
and was effective in the range between 1 and 10 ng/ml (Fig 3B).
Western blot analysis showed strong suppression of IRF1 protein
levels by FGF7 (12 h treatment) in the presence or absence of IFN-a.
However, levels of total and phosphorylated STAT1 (Y701 and
S727) and of RSAD2 were not affected, possibly because of a longer
half-life of these proteins. IRF9 protein levels were down-regulated
by FGF7 in the absence, but not in the presence of IFN-a (Fig 3C).
The suppressive effect of FGF7 on the basal and IFN-a-induced
ISG expression was verified with primary human keratinocytes
(Fig 3D). We only used cells from two donors in this experiment,
but the values were very similar among them.
FGF7 suppresses poly(I:C)-induced ISG and IFN expression
ISGs encode various proteins that control IFN production, such as
the transcription factors IRF7 and IRF1 (Honda et al, 2005; Panda
et al, 2019), and different proteins involved in nucleic acid sensing
(Shaw et al, 2017). Therefore, we tested if FGF signaling also
suppresses IFN expression. When HaCaT cells were treated with
◀
Figure 1. Inhibition of FGFR signaling in keratinocytes promotes IFN and ISG expression.
A, B qRT–PCR for different ISGs relative to Rps29 using epidermal RNA from 8-week-old (A) or 5-day-old or 9-day-old (B) K5-R1/R2 and control (CTRL) mice.
C Confocal microscopy images of epidermal sheets from back skin of K5-R1/R2 and CTRL mice stained for IRF7 and K14, counterstained with DAPI. Arrows denote
nuclear IRF7 (red) in basal and suprabasal keratinocytes of K5-R1/R2 mice. The strong red staining of the stratum corneum (sc) is unspecific background and is more
pronounced in K5-R1/R2 mice due to the increased thickness of this layer.
D qRT–PCR for different ISGs, Ifnb, and Ifnl3 relative to Rps29 using RNA from freshly isolated, non-cultured keratinocytes of K5-R1/R2 and control (CTRL) mice at P7.
E qRT–PCR for ISGs relative to Rps29 using RNA from primary keratinocytes of neonatal CTRL and K5-R1/R2 mice.
F qRT–PCR for ISGs and Cre relative to Rps29 using RNA from primary keratinocytes of neonatal K5-Cre and wild-type (WT) mice.
G Western blot analysis of total (L) and nuclear (N) lysates from immortalized (imm.) keratinocytes of CTRL and K5-R1/R2 mice for IRF1, IRF7, IRF9, Lamin A/C (nuclear
marker, loading control), and GAPDH (cytosolic marker, loading control).
H qRT–PCR for RSAD2 and ISG15 relative to RPLP0 using RNA from HaCaT keratinocytes treated for 48 h with the FGFR inhibitor BGJ398 (3.5 lM) or vehicle in the
presence of serum.
Data information: Scatter plots show mean  SEM. Mean expression levels in CTRL mice or cell cultures were set to 1, and mRNA levels relative to this value are shown.
In (F), expression levels in K5-Cre mice were set to 1. (A) N = 10 mice per genotype, (B) N = 6–14 mice per genotype. (C) Representative images of two experiments.
Magnification bar: 20 lm. (D) N = 5 mice per genotype. (E, F) N = 4–7 cultures (each from a different mouse) per genotype. (G) Representative of three experiments. (H)
N = 6–9 per treatment group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 (Mann–Whitney U-test). Exact P-values are provided in Dataset EV2.
Source data are available online for this figure.
▸
Figure 2. FGF7 and FGF10 suppress the IFN response in keratinocytes.
A Growth factor-starved primary keratinocytes from WT mice were treated for 3 or 6 h with FGF7 (10 ng/ml) or vehicle (CTRL). RNA samples were analyzed by qRT–
PCR for the indicated ISGs relative to Rps29.
B Serum-starved HaCaT keratinocytes were treated for 6 h with FGF7 or FGF10 (each 10 ng/ml). RNA samples were analyzed by qRT–PCR for IRF7 and RSAD2 relative
to RPLP0.
C Serum-starved HaCaT keratinocytes were treated for 16 h with FGF7 (10 ng/ml). Protein lysates were analyzed by Western blot for IRF1, IRF3, IRF9, and GAPDH.
D RNA samples from untreated, serum-starved primary keratinocytes from WT and Ifnar1-KO mice were analyzed by qRT–PCR for Irf7, Rsad2, Oasl2, and Ifnar1
relative to Rps29.
E Growth factor-starved primary keratinocytes from neonatal WT, Ifnar1-KO, or Ifnar1/Ifnlr1-KO mice were treated for 24 h with FGF7 (10 ng/ml). RNA samples were
analyzed by qRT–PCR for Irf7 relative to Rps29.
F HaCaT keratinocytes were transiently transfected with an ISRE-Luciferase reporter construct and starved 24 h after transfection for 9 h. They were then incubated
in the presence or absence of FGF7 (10 ng/ml) for 20 h. Lysates were analyzed using a DualGlo Luciferase Assay.
G, H HaCaT keratinocytes were pre-treated for 2 h with the proteasome inhibitors MG132 (10 lm (G) or epoxomicin (100 nM) (H), followed by a 20-h treatment with
FGF7 (10 ng/ml) or vehicle. RNA samples were analyzed by qRT–PCR for IRF7 and IRF1 relative to RPLP0.
Data information: Scatter plots show mean  SEM. Mean expression levels in CTRL cell cultures (not treated with FGF7 or any inhibitor) were set to 1. In (D) and in the
left panel of (E), expression levels in wt cells were set to 1, while expression levels in untreated IFN receptor knockout cells were set to 1 in the middle and right panel of
(E). (A) N = 8–11 cultures (each from a different mouse) from four experiments. (B) N = 3–5 from one experiment. (C) Representative of 3 experiments. (D, E) N = 5–11
cultures (each from a different mouse) from two experiments. The results with Ifnar1-KO mice were reproduced in two additional experiments. (F) N = 16–18 from 4
experiments. (G) Representative of four experiments, N = 3 per treatment group for each experiment. (H) N = 6 per treatment group from two experiments. ns: non-
significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P < 0.0001 (Mann–Whitney U-test (A, B, D, E, F, H) or t-test for assessment of FGF7 effect (G), with Welch correction
for IRF1. Exact P-values are shown in Dataset EV2.
Source data are available online for this figure.
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poly(I:C), which induces IFN expression by binding to toll-like
receptor 3 (TLR3) (Alexopoulou et al, 2001), expression of IFNB and
of IFNL1 was strongly induced. This was accompanied by a strong
increase in the expression of IRF7, RSAD2, IRF1, CGAS, TLR3, and
DDX58 (Fig 4A). The poly(I:C)-induced increase in the expression
of IFNB, IFNL1, IRF7, RSAD2, IRF1, and DDX58 was significantly
suppressed by FGF7 (Fig 4A), demonstrating that FGF signaling not
only interferes with the IFN response, but also with the expression
of IFNs. The poly(I:C)-induced increase in TLR3 mRNA levels was
also mildly, although non-significantly reduced by FGF7, while
cyclic GMP-AMP synthase (CGAS) expression was not affected
(Fig 4A). The effect of FGF7 was confirmed at the protein level for
total and phosphorylated STAT1 (Y701 and S727), and for phospho-
rylated STAT2 (Y690), reflecting the suppression of IFN production
(Fig 4B and quantification in Fig EV3). As shown before (Figs 2C
and 3C), IRF1 and IRF9 expression was suppressed by FGF7 in the
basal state, but this was overruled at this time point by the strong
effect of poly(I:C) (Fig 4B and quantification in Fig EV3).
FGF signaling promotes replication of Herpes Simplex Virus type
1 (HSV-1) in keratinocytes
The potent effect of FGF signaling on IFN and ISG repression raised
the intriguing possibility that modulation of FGF signaling may affect
viral infection. Since human keratinocytes are the first entry sites for
HSV-1 (Petermann et al, 2015), we used this pathogen to address this
question. Indeed, FGF7 boosted the production of viral glycoprotein
B (Glyc-B) DNA and of glycoprotein D (Glyc-D) protein after HSV-1
infection of HaCaT keratinocytes, while IFN-a had the opposite effect
(Fig 5A and B). 48 h after infection, HSV-1-infected cells had fused,
but were still attached. In the presence of FGF7, however, most
infected cells were detached (Fig 5C). The effect of FGF7 on HSV-1
viral load was dose-dependent (Fig 5D) and was also observed with
human primary keratinocytes from two different donors (Fig 5E). It is
most likely mediated via the FGFR2b splice variant on keratinocytes,
since the high-affinity ligands of this receptor, FGF7 and FGF10,
strongly elevated Glyc-D DNA and protein levels, whereas FGF2,
which binds to FGFR2b with much lower affinity (Zhang et al, 2006),
had only a weak effect (Fig 5F). When we infected epidermal sheets
from mouse tail skin ex vivo with HSV-1 in serum-free medium, the
virus preferentially infected cells of the hair follicles as indicated by
follicular staining for Glyc-D (Fig 5G, middle panel). FGF7 treatment
resulted in a much larger Glyc-D-positive area, and virus-infected
cells were seen throughout the interfollicular epidermis (Fig 5G, right
panel). Promotion of HSV-1 infection of cultured keratinocytes by
FGF7 was even observed in the presence of IFN-a (Fig 5H). There
was still a considerable elevation in viral DNA levels even when
FGF7 was added 4 h after addition of HSV-1 and after removal of the
virus (Fig 5I). While this result does not exclude an effect on viral
entry, it suggests that FGF7 mainly promotes viral replication. Consis-
tent with this assumption, expression of nectin-1 (NECT1), which is
required for HSV-1 entry into keratinocytes (Petermann et al, 2015;
Sayers & Elliott, 2016), was even slightly down-regulated by FGF7
(Fig 5J).
We next treated keratinocytes with FGF7 at different time points
after HSV-1 infection (Fig 6A). FGF7 suppressed ISG expression and
caused a robust increase in HSV-1 DNA when added together with
the virus or 2–4 h post-infection (Fig 6B and C) and was thus
present for 8–12 h. However, when FGF7 was added 8 h post-infec-
tion, suppression of ISG expression and promotion of viral replica-
tion was no longer observed (Fig 6C). Importantly, Glyc-B DNA
levels negatively correlated with the mRNA levels of ISGs and of
IFNL2 (Fig 6B–D). This inverse correlation was also seen at the
protein level: High levels of the HSV-1 Glyc-D protein correlated
with reduced levels of RSAD2, IRF7, IRF9, STAT2, and IRF1, while
there was no correlation with STAT1 and IRF3. In addition, Glyc-D
levels inversely correlated with levels of phosphorylated STAT1 and
STAT2 (Fig 6E). These findings strongly suggest that the FGF7-
◀
Figure 3. FGF7 suppresses IFN-induced ISG expression.
A–C Serum-starved HaCaT keratinocytes were treated with FGF7 (10 ng/ml (A, C) or different concentrations as indicated (B)) and/or IFN-a (500–1,000 U/ml) for 12–
16 h. RNA was analyzed by qRT–PCR for ISGs relative to RPLP0 (A, B) and protein samples by Western blot for total and pSTAT1 (Y701 and S727), IRF1, IRF9, and
RSAD2 and GAPDH (C). The vertical line in the RSAD2 blot indicates a place where the gel was broken. Densitometric quantification of the different blots (N = 3) is
shown on the right.
D Human primary keratinocytes were starved and treated for 12 h with FGF7 (10 ng/ml) and/or IFN-a (1,000 U/ml). RNA samples were analyzed by qRT–PCR for ISGs
relative to RPLP0.
Data information: Scatter plots show mean  SEM. Mean expression levels in CTRL cell cultures were set to 1. (A) N = 5–6 from two independent experiments. (B)
N = 2–3 from one experiment. (C) Representative blot from two experiments. The intensities of the bands were used for the quantification (N = 3). (D) N = 6 replicates
from two experiments with cells from two donors. ns: non-significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P < 0.0001 (2-way ANOVA with Tukey’s multiple
comparisons test (A, D) or t-test with Welch correction for assessment of FGF7 effect (C)). Exact P-values are shown in Dataset EV2.
Source data are available online for this figure.
▸
Figure 4. FGF7 suppresses poly(I:C)-induced IFN and ISG expression.
A Serum-starved HaCaT cells were treated for 24 h with poly(I:C) (5 lg/ml) in the presence or absence of FGF7 (10 ng/ml). RNA samples were analyzed by qRT–PCR for
IFNL1, IFNB, RSAD2, IRF1, IRF7, CGAS, TLR3, or DDX58, relative to RPLP0.
B Serum-starved HaCaT cells were treated for 18 h with poly(I:C) (5 lg/ml) in the presence or absence of FGF7 (10 ng/ml). Protein lysates were analyzed by Western
blot for total and pSTAT1 (Y701 and S727), total and pSTAT2 (Y690), IRF1, IRF3, pIRF3 (S396), IRF9, RIG-1, RSAD2, and GAPDH.
Data information: Scatter plots show mean  SEM. Mean expression levels in cell cultures treated with poly(I:C) only were set to 1, since IFN mRNA levels in non-
treated cells are hardly detectable. (A) N = 6–9 from two experiments. (B) Representative blot from two experiments. Quantification of the bands is shown in Fig EV3.
**P ≤ 0.01, ***P ≤ 0.001 (2-way ANOVA with Tukey’s multiple comparisons test). Exact P-values are shown in Dataset EV2.
Source data are available online for this figure.
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mediated suppression of ISG and also of IFN expression contributes
to the promotion of viral replication.
FGF signaling promotes replication of RNA viruses
The FGF7 effect was not restricted to the DNA virus HSV-1, but it
also promoted replication of the RNA virus lymphocytic chorio-
meningitis virus (LCMV). Expression levels of LCMV nucleoprotein
(NP) were strongly elevated in the presence of FGF7, while IFN-a
had the opposite effect (Fig 6F).
Next, HaCaT cells were infected with two strains of the human
pathogen Zika virus (ZIKV), which naturally gains access to the
body via mosquito bites and can infect cells of the skin, including
keratinocytes (Hamel et al, 2015). The number of cells expressing
the ZIKV envelope protein (ZIKV-ENV) was higher in FGF7-treated
compared to mock-treated cells (Fig 6G). qRT–PCR analysis of ZIKV
RNA demonstrated that FGF7 was also effective when added 2 h
after infection (Fig 6H). Consistent with the important role of ISGs
in the effect of FGF7, MxA (human myxovirus resistance protein)
and OAS1 (20-50-oligoadenylate synthase 1), two ISGs that are highly
expressed during infection by viruses of the Flaviviridae family (Zhu
et al, 2014), were upregulated during ZIKV infection, and FGF7
antagonized this effect (Fig 6I and J).
Inhibition of FGFR signaling is an antiviral strategy
Finally, we determined whether FGFR inhibitors have antiviral
activity. As expected, the FGF7-induced promotion of viral replica-
tion in serum-starved keratinocytes was suppressed by the FGFR
kinase inhibitors AZD4547 and BGJ398 as determined by analysis of
◀
Figure 5. FGF7 promotes HSV-1 replication in human keratinocytes.
A–C Serum-starved HaCaT cells were infected with HSV-1 (MOI = 0.5) in the presence or absence of FGF7 (10 ng/ml) or IFN-a (1,000 U/ml). Viral load was determined
24 h post-infection (hpi) by qPCR for the HSV-1 Glyc-B gene relative to the human b-actin gene (ACTB) (A) or by HSV-1 Glyc-D immunofluorescence (red) and DAPI
counterstaining (blue) (B). (C) Transmission microscopy images of HaCaT cells 48 h post-infection (hpi).
D, E Serum-starved HaCaT cells (D) or human primary keratinocytes (HPK, from two donors) (E) were infected with HSV-1 (MOI = 0.5) in the presence or absence of
FGF7 at the indicated concentrations. Virus load was determined by qPCR for HSV-1 Glyc-B relative to ACTB 24 hpi.
F Serum-starved HaCaT cells were infected with HSV-1 (MOI = 0.5) in the presence or absence of FGF7, FGF10, or FGF2 (10 ng/ml). DNA samples were analyzed by
qPCR for Glyc-D DNA relative to ACTB, and protein lysates were analyzed by Western blot for Glyc-D and vinculin 10 hpi.
G Epidermal sheets from tail skin, infected ex vivo with HSV-1 (MOI = 2)  FGF7 (10 ng/ml), were stained 48 hpi for Glyc-D (red) using DAPI as counterstain (blue).
The infected area (red staining) was measured using ImageJ software. Data are expressed as A.U. = arbitrary unit. Background staining of hairs was subtracted
manually.
H Serum-starved HaCaT cells were infected with HSV-1 in the presence or absence of FGF7 (10 ng/ml) or IFN-a (1,000 U/ml). Viral load was determined 24 hpi by
qPCR for the HSV-1 Glyc-B gene relative to ACTB or by Western blot for the viral protein Glyc-D and GAPDH.
I Serum-starved HaCaT cells were infected with HSV-1 (MOI = 0.5). Four hours hpi, infected cells were washed and incubated in fresh serum-free medium
containing FGF7 (10 ng/ml). Viral load was measured 8 h later by qPCR for Glyc-B relative to ACTB.
J Serum-starved HaCaT keratinocytes were treated for 6 h with FGF7 (10 ng/ml). RNA samples were analyzed by qRT–PCR for NECT1 (encoding nectin-1) relative to
RPLP0.
Data information: Scatter plots show mean  SEM. In (A), and (D–I) mean viral DNA levels or stained area in HSV-1-infected, but non-treated cells were set to 1. In (J),
mean expression levels in CTRL cell cultures were set to 1. (A) N = 16–24 from four independent experiments. (B, C) Representative pictures are shown. (D) N = 6 from
one experiment. (E) N = 6 from two experiments and two donors. (F) N = 4 from two experiments. The Western blot is a representative of two experiments. (G) N = 16–
24 measured areas from 8 mice from 4 experiments. (H, scatter plot) N = 6 from two experiments. The Western blot is a representative of two experiments. (I) N = 8
mice from two experiments. (J) N = 6 from 2 experiments. *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001 (Mann–Whitney U-test). Exact P-values are shown in Dataset EV2.
Magnification bars: 200 lm (B) or 80 lm (C) and 800 lm (G).
Source data are available online for this figure.
▸
Figure 6. FGF7 suppresses virus-induced ISG expression and stimulates replication of different viruses in keratinocytes.
A–E Serum-starved HaCaT cells were infected with HSV-1 (MOI = 0.5)  FGF7 (10 ng/ml), added at the indicated time points (A). 12 h after infection, RNA samples
were analyzed by qRT–PCR for RSAD2, IRF7, and IFNL2 relative to RPLP0 (B); DNA samples were analyzed by qPCR for Glyc-B DNA relative to ACTB (C); and protein
lysates were analyzed by Western blot for Glyc-D, total and phosphorylated STAT1 (Y701), STAT2, and IRF3; for IRF1, IRF7, IRF9, and RSAD2; and for GAPDH or
vinculin (loading controls) (E). Quantification of the Glyc-D, RSAD2, IRF1, IRF7, IRF9, and STAT2 band intensity relative to GAPDH is shown on the right hand side.
(D) shows mean Glyc-B DNA and RSAD2, IRF7, and IFNL2 mRNA levels (based on results shown in Fig 6B and C) in virus-infected cells treated for different periods
with FGF7.
F HaCaT cells were infected with LCMV in the presence or absence of FGF7 (10 ng/ml) or IFN-a (1,000 U/ml) and analyzed for LCMV nucleoprotein (NP) by flow
cytometry 24 hpi. Arbitrary units are shown.
G, H HaCaT cells were infected with ZIKV strains 976 (Uganda isolate) (MOI = 0.1) or PF13/251013-18 (French Polynesia isolate) (MOI = 20) and treated 2 hpi with FGF7
(20 ng/ml) or vehicle (CTRL). Immunofluorescence staining for the ZIKV envelope protein and quantification of the percentage of cells expressing the ZIKV envelope
protein (G) and qRT–PCR analysis of RNA samples for ZIKV RNA (H) 48 hpi is shown.
I, J HaCaT cells were infected with the ZIKV PF13/251013-18 (MOI = 20) in the presence or absence of FGF7 (20 ng/ml). RNA samples were analyzed by qRT–PCR for
OAS1 and MxA relative to RPLP0 72 hpi.
Data information: Scatter plots show mean  SEM. In (B–H and J), results obtained with virus-infected, but non-treated cells were set to 1; in (I), mean expression levels
in non-infected cell cultures were set to 1. (B) N = 4–5 from 2 experiments. (C) N = 4 from 2 experiments. (E): Representative blots of two experiments. (F) N = 5–6 from
two experiments. (G, H) N = 4 from one experiment. (I, J) N = 4–8 from two experiments. Magnification bar in (G): 40 lm. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (Mann–
Whitney U-test). Exact P-values are provided in Dataset EV2.
Source data are available online for this figure.
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Glyc-B DNA and Glyc-D protein levels 24 h after HSV-1 infection
(Fig 7A). In the presence of serum, which contains FGFs, HSV-1
infection was effectively suppressed by treatment with these inhibi-
tors alone or in combination as demonstrated by analysis of Glyc-B
DNA levels or viral titers (Fig 7B and C). Since both inhibitors are
highly selective for FGFR1-3, these findings strongly suggest that
FGFR inhibition is sufficient to suppress viral replication in serum-
containing medium, although a minor contribution of other kinases
that are inefficiently inhibited by AZD4547 and BGJ398 cannot be
excluded.
Finally, we examined the effects of loss of FGFR signaling on HSV-
1 replication in vivo. 48 h after subcutaneous inoculation of HSV-1
into wild-type mice (Aoki et al, 2013), we observed a mild, but signif-
icantly increased expression of Fgf7 (Fig 7D). Notably, the viral load
was significantly lower in K5-R1/R2 compared with control mice
48 h after cutaneous HSV-1 infection as revealed by PCR analysis of
the DNA encoding the immediate-early protein ICP0 (Fig 7E).
Taken together, these results highlight the biological relevance of
the FGF-mediated regulation of ISG expression and the antiviral











































































































































































































































Figure 7. Inhibition of FGFR signaling blocks HSV-1 replication.
A Serum-starved HaCaT cells were infected with HSV-1 (MOI = 0.5) in the presence or absence of FGF7 (10 ng/ml) and the FGFR kinase inhibitors AZD4547 (1 lM) or
BGJ398 (3.5 lM). DNA and protein lysates were analyzed by qPCR for Glyc-B relative to ACTB or by Western blot for Glyc-D and GAPDH, respectively, 16 hpi.
B, C HaCaT cells were cultured in DMEM/10% FCS (B) or DMEM/5% FCS (C) and infected with HSV-1 (MOI = 0.5) in the presence or absence of AZD45347 (1 lM) and/or
BGJ398 (3.5 lM). Viral load was determined by qPCR for Glyc-D relative to ACTB (B) or by measurement of viral titers (plaque-forming units (PFU)) 14 hpi (C).
D, E Adult C57BL/6 wild-type (D) or K5-R1/R2 mice and respective controls (E) were infected subcutaneously with HSV-1 (MOI = 10). RNA from infected skin was
analyzed by qRT–PCR for Fgf7 relative to Rps29 (D), and DNA was analyzed by qPCR for ICP0, normalized to the host gene Tbx15 48 hpi (E).
Data information: Scatter plots show mean  SEM. In (A, B), mean viral DNA levels in HSV-1-infected, but non-treated cells were set to 1. In (C), absolute PFU/ml cell
lysate is shown. In (D), mean expression in non-infected mice (vehicle-injected) was set to 1, and in (E), mean ICP0 DNA levels in Ctrl mice were set to 1. (A) N = 5–6 from
two experiments. (B) N = 12–13 from 4 experiments. (C) N = 6 from two experiments. (D) N = 9–10 infected mouse skin spots from two experiments. (F) N = 20–24
infected mouse skin spots from two experiments. *P ≤ 0.05, **P ≤ 0.01, ****P < 0.0001 (Mann–Whitney U-test). Exact P-values are provided in Dataset EV2.
Source data are available online for this figure.
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Discussion
We identified an unexpected role of FGFR signaling in antiviral
defense, which is mediated at least in part via control of the cellular
IFN response. FGFs exert their early effect on ISG expression at the
transcriptional level and in an FGFR kinase-dependent, but IFN
receptor-independent manner. This conclusion is based on the find-
ings that (i) FGF7 and FGF10 suppressed ISG expression already
within 3–6 h; (ii) the FGF-mediated suppression of ISG expression
was still observed in the absence of the receptors for type I and type
III IFNs; (iii) expression of SOCS1 and SOCS3, which encode inhibi-
tors of the IFN receptor signaling complex, was not upregulated by
FGF7; and (iv) FGF7 suppressed the expression of an ISRE reporter
gene. The effect of FGF7 is likely to involve proteasomal degrada-
tion of a protein required for ISG expression, since it was abolished
in the presence of different proteasome inhibitors. Our results
further suggest an involvement of a combination of the MEK1/2-
ERK1/2 and PI3K-AKT pathways in the FGF7-mediated ISG regula-
tion. A role of MEK/ERK signaling is consistent with the induction
of a type I IFN response in human keratinocytes by MEK inhibitors
(Lulli et al, 2017) and with the down-regulation of the IFN-induced
antiviral response by activated Ras in fibroblasts (Battcock et al,
2006).
The ISREs present in the promoters of ISGs are recognition sites
for the IFN-stimulated gene factor 3 (ISGF3), a complex of IRF9,
pSTAT1, and pSTAT2 (Darnell et al, 1994). ISREs also have an
embedded IRF response element (IRE) (Michalska et al, 2018),
and ISREs and/or IREs are present in the promoters of ISGs
(Ivashkiv & Donlin, 2014). Through binding to ISREs and IREs,
different IRFs, including IRF9, IRF1, and IRF7, regulate ISG expres-
sion (Leviyang et al, 2019; Panda et al, 2019). Since IRF and also
STAT1/2 levels are frequently regulated by ubiquitination and
subsequent proteasomal degradation (Nakagawa & Yokosawa,
2000; Barro & Patton, 2007; Zhao et al, 2016) and since inhibition
of the proteasome blocked the effect of FGF7 on ISG expression,
IRFs and STATs are candidate targets of the rapid effect of FGF7.
Future biochemical/proteomics studies will be required to charac-
terize the ISRE/IRE-bound proteins in the presence or absence of
FGF7 or FGFR inhibitors to further elucidate the molecular mecha-
nism of this pathway.
The two- to threefold down-regulation of the expression of vari-
ous ISGs within a few hours of FGF7 stimulation is likely to be
sustained, since some ISGs encode positive regulators of ISGs, such
as STAT1, STAT2, and several IRFs (Darnell et al, 1994). In particu-
lar, the effect of FGF7 on IRF7, but also on IRF1, which was shown
to regulate IFN expression (Fujita et al, 1989), also provides a likely
explanation for the FGF-mediated impairment of IFN expression in
response to poly(I:C) or viruses. This is likely to be potentiated by
the FGF-mediated suppression of ISGs that encode proteins
involved in pathogen sensing and subsequent induction of IFN
expression.
IFNs and ISGs are known for their multiple activities in the
control of cell proliferation, apoptosis, cancer inhibition, and
immunomodulation (Maher et al, 2007; Lasfar et al, 2016). Thus,
the results presented in this study may have widespread positive or
negative consequences in vivo. It remains to be determined whether
the increased expression of ISGs contributes to the atopic dermati-
tis-like phenotype that develops in K5-R1/R2 mice. This is,
however, not very likely, since ISGs were already upregulated prior
to the development of the phenotype and even before the excessive
infiltration of the skin by immune cells.
By contrast, the effect of FGFs on IFN and ISG expression corre-
lated with a strong suppression of the antiviral defense, a key func-
tion of IFNs. FGF7 mainly promoted viral replication, although an
effect on viral entry cannot be excluded due to the inhibitory effect
of ISGs on different stages of the viral life cycle (Schneider et al,
2014). It has been suggested that HSV-1 enters cells via FGF recep-
tors (Kaner et al, 1990). However, this cannot explain the effect that
we observed, since FGF7 enhanced the viral load, while the entry of
HSV-1 via an FGFR was inhibited by recombinant FGF (Kaner et al,
1990). In addition, our results suggest that the effect of FGFs on
HSV-1 infection is not mediated via nectin-1 expression. This is
further supported by the finding that FGF7 also inhibited replication
of the RNA viruses ZIKV and LCMV. Rather, the effect on different
viruses is consistent with the broad antiviral activities of ISGs
(Schoggins & Rice, 2011).
Interestingly, FGF7 expression is upregulated in wounded/in-
flamed skin (Werner et al, 1992) and also in response to cutaneous
HSV-1 infection (this study). This may promote viral replication at
the site of injury/inflammation through suppression of ISG expres-
sion. Therefore, the beneficial effect of increased FGF7 expression,
which includes promotion of tissue repair and protection from phys-
ical and chemical insults (Finch & Rubin, 2004; Maddaluno et al,
2017), may come with a risk of enhanced viral infections.
The results of our work are likely of medical relevance, since
they suggest the use of FGFR inhibitors for the control of viral infec-
tions in humans. Such an approach would most likely not be con-
fined to the skin. Consistent with this assumption, FGF2 promoted
hepatitis C virion production in hepatoma cells (Van et al, 2016)
and Zika virus infection of human fetal astrocytes (Limonta et al,
2019). Furthermore, FGF7 or FGF2 suppressed the expression of
some ISGs in human lung epithelial cells (Prince et al, 2001), colon
cancer cells (this study), or in human astrocytes, respectively
(Limonta et al, 2019). However, the use of FGFR inhibitors as an
antiviral strategy will require a precise timing of the treatment, since
they may affect tissue healing. Indeed, inhibition of FGFR signaling
impeded the repair of mouse lungs after influenza virus infection
(Quantius et al, 2016). Besides timing, the affected cell type and its
FGFR expression pattern are likely to be relevant. Thus, a subset of
FGFs, which mainly activate FGFR3, inhibited infection of different
types of cancer cells with vesicular stomatitis virus or Coxsackie
virus through an as yet unidentified mechanism that is independent
of ISG regulation (van Asten et al, 2018). Therefore, it will be
important to determine whether certain cancer cells, among which
many show deregulated FGFR signaling (Tanner & Grose, 2016),
may not be protected from viruses by FGFR inhibitors, but rather
become more susceptible. Furthermore, other effects of FGFs on the
viral life cycle need to be considered as recently shown for Dengue
virus, where inhibition of FGFR4 decreased viral replication, but
increased the infectivity of the resulting virions (Cortese et al,
2019).
In spite of these open questions, the prospect of using FGFR
inhibition as an antiviral strategy is promising, since FGFR kinase
inhibitors, FGFR neutralizing antibodies, or FGF ligand traps are
in clinical trials for the treatment of different types of cancers
and are generally well tolerated (Touat et al, 2015; Tanner &
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Grose, 2016). Obviously, such a novel indication for FGFR inhibi-
tors will require intensive studies regarding dosing, mode of
application, efficacy against different viruses, and side effects in
virus-infected patients. Nevertheless, the effort seems to be justi-
fied given the limited options for the treatment of viral infections,
of which some have a high mortality rate or for which vaccines
are not yet available, such as SARS-CoV-2. Virostatic agents,
which interfere with the viral life cycle, are frequently employed.
However, they are most often virus-specific and thus susceptible
to viral variation, and they often exhibit high toxicity. Thus,
improved strategies are urgently needed, and FGFR inhibition is a
fundamentally different approach.
Materials and Methods
Antibodies, recombinant proteins, and chemical inhibitors
The following recombinant proteins and chemical inhibitors were
used: Human FGF7 (100-19, PeproTech Inc., Rocky Hill, NJ or R&D
Systems, Minneapolis, MN), human FGF10 (100-26, PeproTech
Inc.), human FGF2 (100-18, PeproTech Inc.), human IFN-a (300-
02AA, PeproTech Inc), FGFR1/2/3 inhibitors AZD4547 (S2801, Sell-
eckchem, Houston, TX) and BGJ398 (NVP-BGJ398; S2183, Selleck-
chem), PI3K inhibitor LY294002 (InvivoGen, San Diego, CA),
AKT1/2 inhibitor A6730 (A6730, Sigma, Munich, Germany), Mek1/
2 inhibitor U0126 (662005, Calbiochem, San Diego, CA), PLC-c inhi-
bitor U73122 (1278, Tocris, Bristol, UK), and proteasome inhibitors
MG132 (S2619 Selleckchem), bortezomib (PS-341) (S1013, Selleck-
chem), and epoxomicin (E3652, Sigma).
Genetically modified mice and infection of mice with HSV-1
K5-R1/R2 and control mice (mice with floxed fgfr1/fgfr2 alleles, but
without Cre, or K5-Cre mice with wild-type fgfr alleles) in C57BL/6
genetic background and mice lacking IFNAR1 or both IFNAR1 and
IFNLR1 in C57BL/6 genetic background were described previously
(Ank et al, 2008; Mordstein et al, 2008; Yang et al, 2010). They
were maintained under specific pathogen-free conditions and
received food and water ad libitum. For HSV-1 infection, female
mice at the age of 8–10 weeks were shaved, and 24 h later, each
mouse received four subcutaneous injections of 50 ll HSV-1
(MOI = 10) on the flank. 48 h later, they were sacrificed and the
amount of ICP0 DNA in the injected skin was determined using
primers 50-ATA AGT TAG CCC TGG CCC CGA-30 and 50-GCT GCG
TCT CGC TCC G-30. ICP0 DNA levels were normalized to the host
Tbx15 DNA (primers: 50-TCC CCC TTC TCT TGT GTC AG-30 and 50-
CGG AAG CAA GTC TCA GAT CC-30) (Mohn et al, 2009). For the
establishment of primary keratinocytes, we used neonatal mice at
P3 from both genders. Mouse maintenance and all animal experi-
ments were performed according to Swiss Law and approved after
in-depth review and approval by the local veterinary authorities of
Zurich, Switzerland (Kantonales Veterinäramt Zürich).
Separation of dermis from epidermis of mouse back skin
Separation of epidermis from dermis was achieved either by heat
shock treatment (30 s at 55–60°C followed by 1 min at 4°C, both in
PBS), by incubation for 50–60 min at 37°C in 0.143% dispase
(17105-041, Life Technologies, Carlsbad, CA) in DMEM or by incu-
bation in 0.8% trypsin (27250-018, Life Technologies)/DMEM for
15–30 min at 37°C. For dispase and trypsin treatment, the subcuta-
neous fat was gently scraped off with a scalpel prior to incubation.
Immunofluorescence analysis of skin sections and cultured cells
Frozen mouse back skin sections were fixed with cold methanol, and
unspecific binding sites were blocked with PBS containing 2% bovine
serum albumin (BSA) (Sigma)/1% fish skin gelatin (Sigma)/0.05%
Triton X-100 (Carl Roth GmbH, Karlsruhe, Germany) for 2 h at room
temperature. Samples were then incubated overnight at 4°C with the
primary antibodies diluted in the same buffer. After three washes
with PBS-T [1 × PBS/0.1% Tween-20 (Carl Roth GmbH)], slides were
incubated at room temperature for 4 h with secondary antibodies and
DAPI (40,6-diamidino-2-phenylindole dihydrochloride) (Sigma) as
counterstain and washed with PBS-T again and mounted with
Mowiol (Hoechst, Frankfurt, Germany). Stained sections were photo-
graphed using a Leica SP1-2 confocal microscope equipped with a
63 × 0.6–1.32 NA (Iris) PL Apo Oil objective. Data acquisition was
performed using Leica Confocal Software (Leica, Wetzlar, Germany).
For immunofluorescence analysis of cultured cells, cells were washed
in PBS and then either fixed for 5 min with cold methanol for staining
with antibodies against ZO-1 and IRF7, or with 4% paraformaldehyde
(PFA) (Sigma) for 20 min at RT for Glyc-D staining. PFA-fixed cells
were then incubated for 10 min with 0.5% Triton X-100 in PBS. After
1 h blocking in PBS containing 2% BSA, cells were stained with
primary antibodies for 1 h in the same blocking buffer. After three
washes with PBS, cells were incubated with secondary antibodies
and DAPI. Stained cells were photographed using a Zeiss Imager.A1
microscope equipped with an Axiocam MRm camera and EC Plan-
Neofluar objectives (10×/0.3, 20×/0.5). For data acquisition, we used
the Axiovision 4.6 software (all from Carl Zeiss Inc., Jena, Germany).
The Glyc-D positive area was quantified by digital pixel measure-
ments using ImageJ software. Antibodies used for immunofluores-
cence staining are listed in Appendix Table S1.
RNA isolation and qRT–PCR
Total RNA from the epidermis of mice or from total skin was isolated
with Trizol followed by purification with the RNeasy Mini Kit, includ-
ing on-column DNase treatment (Qiagen, Hilden, Germany). Total
RNA from cultured cells was extracted directly with the RNeasy Mini
Kit. cDNA was synthesized using the iScript kit (Bio-Rad Laborato-
ries, Berkeley, CA). Relative gene expression was determined using
the Roche LightCycler 480 SYBR Green system (Roche, Rotkreuz,
Switzerland). Expression of the genes encoding ribosomal protein
L29 (Rpl29) or ribosomal protein lateral stalk subunit P0 (RPLP0) was
used for normalization of expression levels of murine or human
genes, respectively, unless otherwise indicated in the figure legends.
Primers used for qRT–PCR are listed in Appendix Table S2.
Gene expression profiling and bioinformatic analysis
Epidermis from nine K5-R1/R2 and nine control mice at P18 was
separated from the dermis and immediately frozen in liquid nitro-
gen. Samples from three mice per genotype were pooled and
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subjected to Affymetrix microarray hybridization (N = 3 pools per
genotype) (Beyer et al, 2008). Genes, which were significantly and
more than 1.5 log2 (fold change) regulated in K5-R1/R2 compared
with control mice, were entered into EnrichR to discover functional
enrichments of the FGF-regulated genes (Kuleshov et al, 2016).
Tables referring to Gene Ontology (GO) Biological Process 2017b
and Reactome 2016 were downloaded and formatted into tables.
Lists of significantly upregulated genes, ISGs, and original tables
from functional enrichments can be found in Dataset EV1.
Cell culture
Primary keratinocytes were isolated from neonatal mice (Yang et al,
2010) and cultured for 3 days in defined keratinocyte serum-free
medium (dK-SFM) (Invitrogen, Carlsbad, CA) supplemented with
10 ng/ml EGF, 1010 M cholera toxin, and 100 U/ml penicillin/
100 lg/ml streptomycin (Sigma). Plates were coated with collagen
IV (Sigma) prior to seeding the cells.
Human primary foreskin keratinocytes were established from fore-
skin (Strittmatter et al, 2016). Foreskin samples had been obtained
upon informed written consent of the parents and upon approval by
the local ethical committee (KEK-ZH-Nr. 2015-0198) and according to
the Declaration of Helsinki Principles. They were cultured in CnT-
Prime Epithelial Cell Culture Medium (CELLnTEC, Bern, Switzerland)
and used for experiments between passages 3 and 5.
HaCaT keratinocytes (Boukamp et al, 1988) were obtained from
the owner, Prof. P. Boukamp, German Cancer Research Center
Heidelberg, and Caco-2 colon cancer cells were from Sigma. Both
cell lines were cultured in DMEM (Sigma) supplemented with 10%
FCS (Thermo Fisher Scientific, Waltham, MA).
For treatment of cells with FGF7, FGF10, FGF2 (Peprotech;
10 ng/ml, unless otherwise indicated in the legends), IFN-a (Pepro-
tech, 500–1,000 U/ml), or poly(I:C) (Sigma, 5 lg/ml, unless other-
wise indicated in the legends), cells were grown to confluency,
starved overnight in serum-free medium, and treated for different
time periods. In some experiments, cells were pre-incubated with
different inhibitors or vehicle (DMSO) for 2–3 h at 37°C, prior to
treatment with FGF7.
Cell transfection and luciferase assay
Transient transfection of HaCaT cells was performed with a TK-
Renilla luciferase expression vector and the pGL4.45[luc2P/ISRE/
Hygro] reporter vector (Promega, Fitchburg, WI), the latter contain-
ing five copies of an ISRE that drives transcription of the luciferase
reporter gene. Cells were seeded into 24-well plates, cultured for
24 h, and transfected using XfectTM (Takara, Kusatsu, Japan). Subse-
quently, cells were starved in serum-free medium overnight, then
treated with FGF7 (10 ng/ml) for 20 h, lysed, and assayed with a
dual-luciferase assay system (Promega) according to the manufac-
turer’s instructions. Relative light units were measured in a GloMax
Discover Microplate (Promega). Firefly luciferase activity was
normalized to Renilla luciferase activity (transfection control).
Preparation of protein lysates and Western blot
Cells were harvested in T-PER tissue protein extraction reagent
(Pierce, Rockford, IL) containing Complete Protease Inhibitor Cocktail
(Roche). Lysates were cleared by centrifugation (16,000 g, 30 min,
4°C), snap-frozen, and stored at 80°C. The protein concentration
was determined using the BCA Protein assay (Pierce). Proteins were
separated by SDS–PAGE and transferred onto nitrocellulose
membranes. Membranes were incubated with primary antibodies
and, subsequently, antibody-bound proteins were detected with
horseradish peroxidase-coupled antibodies against goat-IgG (Sigma),
rabbit-IgG, or mouse IgG (all from Promega). Antibodies used for
Western blot analysis are listed in Appendix Table S1.
HSV-1 production and cell infection
HSV-1 was produced as described (Strittmatter et al, 2016). Subcon-
fluent keratinocytes were starved overnight in serum-free medium
and then incubated with HSV-1 (MOI = 0.5) in the presence or
absence of FGF7, FGF10, or FGF2. Where indicated, infection was
preceded by treatment with AZD4547 (Selleckchem, 1 lM), BGJ398
(Selleckchem, 3.5 lM), or DMSO (vehicle) for 3 h before treatment
with FGF7. Infected cells were then cultured for 10-16 h before the
assessment of viral load. Alternatively, subconfluent HaCaT cells
were infected in DMEM/5% FCS with HSV-1 (MOI = 0.5) in the
presence or absence of AZD4547 and/or BGJ398 and used for the
analysis of viral load 14 h later.
Preparation of genomic and viral DNA from HSV-1-infected cells
Genomic and viral DNA were obtained from infected cells as previ-
ously described (Strittmatter et al, 2016). Samples were used for
quantitative PCR to measure HSV-1 virus load. Primers for amplifi-
cation of the human b-actin DNA (50-TAC TCC TGC TTG CTG ATC
CAC-30 and 50-TGT GTG GGG AGC TGT CAC AT-30) and the viral
glycoprotein B (Glyc-B) DNA (50-CGC ATC AAG ACC ACC TCC TC-30
and 50-GCT CGC ACC ACG CGA-30) were used.
Analysis of HSV-1 viral titers
Viral titers were measured using plaque assay. Infected cells were
scraped in 500 ll DMEM and lysed by single freeze-thawing. 24-well
plates with Vero cells were infected at 37°C for 2 h with serial 10-
fold dilutions of the cell lysate. After infection, the lysate was
removed and the cells were washed twice with PBS and overlaid
with DMEM containing 0.7% agarose. Two days later, the cells were
fixed and stained overnight with a solution containing 0.2% crystal
violet, 11% formaldehyde, 2% ethanol, and 2% paraformaldehyde.
The next day, the plates were washed with water. Plaques were
counted and plaque forming units (PFUs) were calculated taking
into consideration the dilution factor.
Ex vivo HSV-1 infection
HSV-1 infection of mouse tail epidermis was previously described
(Rahn et al, 2015). Briefly, skin was prepared from the tails of 3-
month-old mice. The epidermis was separated from the dermis by
dispase treatment (5 mg/ml). After floating the epidermal sheets on
serum-free DMEM overnight, they were incubated with HSV-1 alone
(MOI = 2) or in combination with FGF7 (10 ng/ml) for 48 h and
subsequently fixed in 4% PFA for 1 h at RT. Tissues were incubated
in blocking solution (PBS 2% BSA/1% fish skin gelatin/0.05%
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Triton X-100) for 2 h at RT and stained overnight at 4°C with an
anti-Glyc-D antibody. After three washes in PBS, epidermal sheets
were incubated for 4 h with AF555-conjugated anti-mouse IgG and
DAPI diluted in PBS/0.05% Triton X-100 at RT and mounted with
their basal side on top of a specimen slide using Mowiol.
LCMV infection and flow cytometric analysis
Subconfluent HaCaT cells were serum-starved overnight and incu-
bated overnight at 37°C with LCMV (MOI 0.05 and 0.2). Cells were
detached from the 12-well plate using 1% trypsin and fixed/perme-
abilized in 500 ll 2 × FACS Lyse (Becton Dickinson, Franklin Lakes,
NJ) with 0.05% Tween-20 for 10 min at room temperature. After
washing, intracellular staining was performed for 30 min at room
temperature using the LCMV nucleoprotein-specific antibody VL-4.
After washing, they were resuspended in PBS/1% PFA. Flow cyto-
metric analysis was performed using an LSRII flow cytometer (Bec-
ton Dickinson). Raw data were analyzed using FlowJo software
(Tree Star Inc, Ashland, OR).
ZIKV infection
HaCaT cells were seeded on a four-well tissue chamber on a PCA
slide (5 × 104/chamber). After overnight serum starvation, cells
were infected with the ZIKV strains Uganda (strain 976) (MOI = 0.1)
(kindly provided by the European Virus Archive goes Global (EVAg)
project) or French Polynesia (PF13/251013-18) (MOI = 20). Two
hours post-infection, cells were treated with 20 ng/ml FGF7 or left
untreated. Culture medium  FGF7 was changed every day. 48 h
post-infection, cells were either analyzed by immunofluorescence
using a Flavivirus group-specific antibody (4G2) detecting the ZIKV
envelope protein (ZIKV-Env) or harvested and analyzed for ZIKV
expression levels by qRT–PCR relative to human RPL27 (ZIKV
primers: 50-AGA TCC CGG CTG AAA CAC TG-30; 50-TTG CAA GGT
CCA TCT GTC CC-30).
Alternatively, HaCaT cells were seeded in six-well plates. After
overnight serum starvation, confluent cells were infected with the
ZIKV strain French Polynesia (PF13/251013-18) (MOI = 20) in the
presence or absence of FGF7 (20 ng/ml). 72 h post-infection, cells
were analyzed for OAS1 and MxA expression levels by qRT–PCR
relative to RPL27.
Statistical analysis
For all experiments, the sample size was estimated based on previ-
ous experience. There was no exclusion of any animal or data point.
Analysis of stained skin sections or epidermal sheets was performed
blinded by the investigators. Group allocation of the mutant mice
could not be performed blinded, because the phenotype of the K5-
R1/R2 mice is obvious macroscopically and histologically. Experi-
ments were performed at least twice, and the number of replicate
experiments is indicated in the figure legends.
Statistical analysis was performed using the PRISM software
(Graph Pad Software Inc., San Diego, CA). Mann–Whitney U-test
for non-Gaussian distribution or t-test with Welsh correction was
used for experiments examining differences between two groups.
For comparison of more than two groups, we used Brown-
Forsythe test to verify equal variance between groups, followed
by two-way ANOVA and Tukey’s multiple comparisons post-hoc
tests.
Data availability
The datasets produced in this study are available in the following
databases: Microarray data: Gene Expression Omnibus GSE11
1274 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1
11274).
Expanded View for this article is available online.
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Viral infections are a major threat to human health. Combating such
infections and prevention of a pandemic requires the development of
vaccines, but also of efficient therapeutics. Unfortunately, many thera-
peutics are virus-specific and/or have high toxicity. Therefore, the
development of novel approaches for the treatment of viral infections
is essential.
Results
We identified a previously uncharacterized role of fibroblast growth
factors (FGFs) in antiviral defense. FGFs efficiently suppress the inter-
feron response and thus the expression of major antiviral genes and
proteins under basal conditions and in response to interferon treat-
ment or viral infections, while FGF receptor inhibition has the oppo-
site effect.
Impact
Our study suggests the use of FGF receptor inhibitors for the treat-
ment of viral infections. This is a promising approach, since such inhi-
bitors are already in clinical trials for the treatment of different types
of cancers and are relatively well tolerated. Due to the widespread
activities of FGFs and interferons, it will also be important to study
the relevance of their unexpected cross-talk described in this study in
various other human diseases as well as in tissue repair.
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